We plan to develop multiple products using Crisper-Cas9 technology for treating cancers and genetic disorders. Gene-edited adult hematopoietic stem cells for treating Thalassemia and Sickle cell disease, gene edited allogenic CAR T cells for treating different cancers, and gene ed-ited cells for treating monogenic genetic disorders are in our priority.
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.
Eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.